Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629129 | MILLICENT | Pharmaceutical compositions |
Aug, 2028
(4 years from now) | |
US8957054 | MILLICENT | Pharmaceutical compositions |
Jan, 2030
(5 years from now) | |
US8268806 | MILLICENT | Pharmaceutical compositions |
Mar, 2031
(6 years from now) |
Intrarosa is owned by Millicent.
Intrarosa contains Prasterone.
Intrarosa has a total of 3 drug patents out of which 0 drug patents have expired.
Intrarosa was authorised for market use on 16 November, 2016.
Intrarosa is available in insert;vaginal dosage forms.
Intrarosa can be used as intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Drug patent challenges can be filed against Intrarosa from 16 November, 2020.
The generics of Intrarosa are possible to be released after 19 March, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 16, 2021 |
Drugs and Companies using PRASTERONE ingredient
NCE-1 date: 16 November, 2020
Market Authorisation Date: 16 November, 2016
Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Dosage: INSERT;VAGINAL